512 Stock Overview
An investment holding company, engages in the research and development, manufacture, and sale of pharmaceutical preparations and medical devices, biotechnology and healthcare products, and pharmaceutical raw materials. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
Rewards
Risk Analysis
No risks detected for 512 from our risk checks.
Grand Pharmaceutical Group Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$4.34 |
| 52 Week High | HK$5.62 |
| 52 Week Low | HK$3.17 |
| Beta | 0.73 |
| 11 Month Change | -7.46% |
| 3 Month Change | 3.33% |
| 1 Year Change | -5.45% |
| 33 Year Change | -34.54% |
| 5 Year Change | -2.03% |
| Change since IPO | -83.31% |
Recent News & Updates
Recent updates
Grand Pharmaceutical Group Limited (HKG:512) Looks Inexpensive But Perhaps Not Attractive Enough
Sep 19
Grand Pharmaceutical Group (HKG:512) Is Paying Out A Larger Dividend Than Last Year
Jun 05Market Participants Recognise Grand Pharmaceutical Group Limited's (HKG:512) Earnings
May 22Grand Pharmaceutical Group (HKG:512) Will Pay A Larger Dividend Than Last Year At HK$0.26
Apr 25Grand Pharmaceutical Group (HKG:512) Will Pay A Larger Dividend Than Last Year At HK$0.26
Mar 25We Think Grand Pharmaceutical Group (HKG:512) Can Stay On Top Of Its Debt
Oct 20Here's Why We Think Grand Pharmaceutical Group (HKG:512) Is Well Worth Watching
Sep 26Grand Pharmaceutical Group's (HKG:512) Dividend Will Be Increased To HK$0.14
Jun 04Is Grand Pharmaceutical Group (HKG:512) A Risky Investment?
May 05Grand Pharmaceutical Group (HKG:512) Seems To Use Debt Quite Sensibly
Nov 21Is Grand Pharmaceutical Group Limited (HKG:512) Trading At A 43% Discount?
Sep 05Grand Pharmaceutical Group (HKG:512) Seems To Use Debt Quite Sensibly
Aug 16Here's Why We Think Grand Pharmaceutical Group (HKG:512) Is Well Worth Watching
Jul 28Grand Pharmaceutical Group's (HKG:512) Dividend Will Be HK$0.11
May 29Is Grand Pharmaceutical Group Limited (HKG:512) Trading At A 45% Discount?
Apr 08Grand Pharmaceutical Group (HKG:512) Has A Rock Solid Balance Sheet
Mar 22If You Like EPS Growth Then Check Out Grand Pharmaceutical Group (HKG:512) Before It's Too Late
Jan 24These 4 Measures Indicate That Grand Pharmaceutical Group (HKG:512) Is Using Debt Safely
Dec 13Grand Pharmaceutical Group Limited's (HKG:512) Intrinsic Value Is Potentially 45% Above Its Share Price
Nov 27With EPS Growth And More, China Grand Pharmaceutical and Healthcare Holdings (HKG:512) Is Interesting
Oct 25China Grand Pharmaceutical and Healthcare Holdings (HKG:512) Seems To Use Debt Rather Sparingly
Sep 01Do China Grand Pharmaceutical and Healthcare Holdings's (HKG:512) Earnings Warrant Your Attention?
Jul 12Shareholder Returns
| 512 | HK Pharmaceuticals | HK Market | |
|---|---|---|---|
| 7D | -7.7% | 0.07% | -0.6% |
| 1Y | -5.4% | -10.2% | 9.6% |
Return vs Industry: 512 exceeded the Hong Kong Pharmaceuticals industry which returned -10.2% over the past year.
Return vs Market: 512 underperformed the Hong Kong Market which returned 9.6% over the past year.
Price Volatility
| 512 volatility | |
|---|---|
| 512 Average Weekly Movement | 5.7% |
| Pharmaceuticals Industry Average Movement | 6.8% |
| Market Average Movement | 8.9% |
| 10% most volatile stocks in HK Market | 19.2% |
| 10% least volatile stocks in HK Market | 4.3% |
Stable Share Price: 512 has not had significant price volatility in the past 3 months compared to the Hong Kong market.
Volatility Over Time: 512's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1995 | 10,775 | Chao Zhou | www.grandpharm.com |
Grand Pharmaceutical Group Limited, an investment holding company, engages in the research and development, manufacture, and sale of pharmaceutical preparations and medical devices, biotechnology and healthcare products, and pharmaceutical raw materials. The company offers respiratory, ophthalmology, cerebro-cardiovascular emergency, and biotechnology related products. It manufactures and sells pharmaceutical, taurine, agrochemicals, chemical medicine, and amino acid series products.
Grand Pharmaceutical Group Limited Fundamentals Summary
| 512 fundamental statistics | |
|---|---|
| Market cap | HK$15.20b |
| Earnings (TTM) | HK$2.41b |
| Revenue (TTM) | HK$10.59b |
6.3x
P/E Ratio1.4x
P/S RatioIs 512 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 512 income statement (TTM) | |
|---|---|
| Revenue | HK$10.59b |
| Cost of Revenue | HK$4.34b |
| Gross Profit | HK$6.25b |
| Other Expenses | HK$3.84b |
| Earnings | HK$2.41b |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.69 |
| Gross Margin | 59.00% |
| Net Profit Margin | 22.75% |
| Debt/Equity Ratio | 28.1% |
How did 512 perform over the long term?
See historical performance and comparison